Adverum Biotechnologies, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 117.17 million compared to USD 154.54 million a year ago. Basic loss per share from continuing operations was USD 11.6 compared to USD 15.6 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.19 USD | -2.13% | -18.96% | +22.08% |
Mar. 21 | Adverum Biotechnologies Files $200 Million Mixed Shelf | MT |
Mar. 19 | RBC Cuts Price Target on Adverum Biotechnologies to $2 From $3, Keeps Sector Perform, Speculative Risk | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.08% | 191M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ADVM Stock
- News Adverum Biotechnologies, Inc.
- Adverum Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023